Organic Active Ingredients TRIZ Cases

Alpha B crystallin protein restores titin elasticity to reduce cardiomyocyte stiffness and treat diastolic dysfunction.

Chromatographic separation reduces cholesterol below 1% while maintaining phospholipid levels between 50 and 60 percent.

Modified chemical structures accommodate secondary mutations in TGFBR2 and FLT3 kinases to maintain treatment effectiveness against resistant variants.

Organic acid conversion transforms unstable viscous ketamine metabolites into processable crystalline solids, achieving high oral bioavailability.

Dividing Cas9, guide RNA, and therapeutic genes into separate AAV vectors reduces off-target effects while maintaining insertion efficiency.

Iota-carrageenan formulation eliminates stinging from povidone-iodine while maintaining antiviral efficacy.

Triethanolamine buffer system maintains RNA integrity in liquid formulations, resolving the contradiction between storage stability and cold chain complexity.

Metaxalone formulation uses sodium lauryl sulfate, HPMC, and vinylpyrrolidone-vinyl acetate copolymer to overcome low aqueous solubility and slow absorption.

Segmenting the total dose into multiple delayed release units reduces mean plasma Cmax by at least 5% while maintaining therapeutic efficacy.

Anti-CD38 antibodies mediate immune attack on acute myeloid leukemia cells, resolving low survival rates by inducing targeted apoptosis.

Tetragonal crystal structure reduces hygroscopicity and improves flow properties for pharmaceutical formulations.

Combining azelastine and alprazolam creates a dual-action pharmaceutical composition.

Tricyclic amino compounds target chemokine receptors to reduce hot flashes without hormone replacement therapy risks.

Segmenting CCR10 targeting with a specific heterocyclic compound resolves the trade-off between broad chemokine modulation and selective receptor inhibition.

A prodrug links an antifungal moiety to a glycosyl trigger via a self-immolative spacer for targeted release.

Subcutaneously implantable pellet formulations provide extended release of opioid antagonists, maintaining consistent therapeutic levels without daily dosing.

Synergist compounds enhance antiviral potency against resistant Hepatitis C variants, enabling interferon-free treatment across all genotypes.

Polymeric conjugates deliver MEK and BRAF inhibitors to tumor cells, reducing systemic toxicity while preventing acquired resistance.

Self-immolative linker segments PBD dimers to resolve stability-toxicity trade-offs in antibody-drug conjugate design.

Tricyclic pyrazinopyrrolopyrimidine compounds bind with high affinity to the CFTR channel, resolving low potency and metabolic instability of prior inhibitors.

Modified release formulations of pridopidine employ rate controlling excipients to lower peak plasma concentrations while maintaining therapeutic efficacy.

Glycine dipeptides mediate preservative action to reduce ocular irritation while maintaining broad-spectrum antimicrobial activity.

Fused heterocyclic compound inhibits PDE10A enzyme to treat schizophrenia while minimizing extrapyramidal syndrome risks.

Spray-dried triptan powders resolve formulation stability trade-offs by enabling rapid pulmonary delivery of migraine medication.

Novel C2-C5-alkyl-substituted imidazole bisphosphonates inhibit bone resorption through mevalonate pathway modulation.

Cyclic anhydrides convert open chain impurities into water-soluble sodium salts, eliminating costly derivatization and crystallization steps.

Targeting the MTV protease enzyme prevents transcription and replication, addressing oncogenic potential beyond simple viral load reduction.

Mild alkaline reaction isolates stable indacaterol free base, resolving impurity and yield trade-offs.

Thiazolyl acyl sulfonamides target the voltage-sensitive domain of NaV1.7 channels to provide selective analgesic effects with reduced side effects.

Histidine-rich peptide coacervates encapsulate insulin via liquid-liquid phase separation to enable glucose-triggered release.

Selective LSD1 inhibition suppresses NFkB-driven inflammation without compromising IRF1-mediated antiviral responses.

Novel 7-substituted 1-arylnaphthyridine-3-carboxamides act as positive allosteric modulators of the muscarinic M2 receptor.

Conjugates antisense oligonucleotides with cell-penetrating peptides to enhance cellular uptake in muscle tissues.

Ortho-nitrobenzaldehyde precursors with TMEDA additives achieve high radiochemical yield, reducing non-specific binding in S1P1 receptor imaging.

Oxidized alginate and methacrylated gelatin form coacervate microdroplets under physiological conditions.

Combining anti-CD123 immunoconjugates with BCL-2 inhibitors reduces toxicity while enhancing antitumor activity in hematological malignancies.

Combining bortezomib with the CRM1 inhibitor KPT330 induces apoptosis in cancer cells.

Formula I heteroarylaminosulfonamides correct defective protein folding and trafficking to resolve limited therapeutic options for cystic fibrosis patients.

A segmented pharmaceutical formulation delivers reboxetine via immediate and controlled release components to generate two distinct plasma concentration maxima.

Cyclodextrin inclusion complexes solubilize hydrophobic drugs to penetrate the cornea, reducing toxicity while enhancing posterior segment bioavailability.

Dual activity compounds act as ORL-1 antagonists to prevent constipation while maintaining analgesic efficacy.

Powdered eggshell membrane composition reduces fasting blood glucose concentrations through oral administration of natural biochemical components.

Monoacylated benzo crown ether compounds self-assemble into stable ion channels that prevent membrane lysis and reduce cytotoxicity.

Combining berberine with vitamin B12 promotes transcobalamin II receptor synthesis to maintain metabolic control.